Blog

Arndt Vogel: Outcome of patients with HCC who achieved CR to ICI-based systemic therapy

Arndt Vogel/X

Dec 1, 2024, 16:34

Arndt Vogel: Outcome of patients with HCC who achieved CR to ICI-based systemic therapy

Arndt Vogel shared on X:

“Outcome of patients with HCC who achieved CR to ICI-based systemic therapy

Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy

Authors: Scheiner, Bernhard; Kang, Beodeul; Balcar, Lorenz; Radu, Iuliana-Pompilia; Reiter, Florian P.; Adžić, Gordan; Guo, Jiang; Gao, Xu; Yuan, Xiao; Cheng, Long; Gorgulho, Joao; Schultheiss, Michael; Peeters, Frederik; Hucke, Florian; Ben Khaled, Najib; Piseddu, Ignazio; Philipp, Alexander; Sinner, Friedrich; D’Alessio, Antonio; Pomej, Katharina; Saborowski, Anna; Bathon, Melanie; Schwacha-Eipper, Birgit; Zarka, Valentina; Lampichler, Katharina; Nishida, Naoshi; Lee, Pei-Chang; Krall, Anja; Saeed, Anwaar; Himmelsbach, Vera; Tesini, Giulia; Huang, Yi-Hsiang; Vivaldi, Caterina; Masi, Gianluca; Vogel, Arndt; Schulze, Kornelius; Trauner, Michael; Djanani, Angela; Stauber, Rudolf; Kudo, Masatoshi; Parikh, Neehar D.; Dufour, Jean-François; Prejac, Juraj; Geier, Andreas; Bengsch, Bertram; von Felden, Johann; Venerito, Marino; Weinmann, Arndt; Peck-Radosavljevic, Markus; Finkelmeier, Fabian; Dekervel, Jeroen; Ji, Fanpu; Wang, Hung-Wei; Rimassa, Lorenza; Pinato, David J.; Bouattour, Mohamed; Chon, Hong Jae; Pinter, Matthias

RWD, 3933 patients

1- and 3-year RFS: 78% and 55%

1- and 3-year OS: 98% and 86%

Just great to report RFS in advanced HCC with ICI

only 4%, but we are getting there…”

Arndt Vogel: Outcome of patients with HCC who achieved CR to ICI-based systemic therapy

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.